G1 Therapeutics, Inc. (GTHX) News

G1 Therapeutics, Inc. (GTHX): $21.36

-0.17 (-0.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GTHX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 486

in industry

Filter GTHX News Items

GTHX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GTHX News Highlights

  • 500 - Internal server error
  • Over the past 24 days, the trend for GTHX's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • ES, JACK and LOGC are the most mentioned tickers in articles about GTHX.

Latest GTHX News From Around the Web

Below are the latest news stories about G1 Therapeutics Inc that investors may wish to consider to help them evaluate GTHX as an investment opportunity.

G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors

RESEARCH TRIANGLE PARK, N.C., June 18, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board of Directors. With more than 30 years of experience in the life sciences industry, she has a proven track record of leading life sciences businesses, guiding products from clinical development through approval and global commercialization, and enabling companies to optimize the potential of innovati

Yahoo | June 18, 2021

G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference. The fireside chat will take place on June 22nd at 9:20 AM EDT. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com. About G1 The

Yahoo | June 16, 2021

G1 Therapeutics initiates phase II trial of Cosela in metastatic bladder cancer

No summary available.

BioWorld | June 15, 2021

G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA (trilaciclib) in Bladder Cancer

- The Primary Endpoint of PRESERVE 3 Will Assess the Anti-Tumor Efficacy of COSELA with Platinum-Based Chemotherapy Followed by COSELA in Combination with Immune Checkpoint Inhibitor Avelumab in 90 Patients with Metastatic Urothelial Carcinoma (mUC) - RESEARCH TRIANGLE PARK, N.C., June 14, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today

Wallstreet:Online | June 14, 2021

G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer

- The Primary Endpoint of PRESERVE 3 Will Assess the Anti-Tumor Efficacy of COSELA with Platinum-Based Chemotherapy Followed by COSELA in Combination with Immune Checkpoint Inhibitor Avelumab in 90 Patients with Metastatic Urothelial Carcinoma (mUC) -RESEARCH TRIANGLE PARK, N.C., June 14, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated PRESERVE 3, a Phase 2, randomized, open-label study of COSELA™

Yahoo | June 14, 2021

Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Logicbio Therapeutics (LOGC)

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on G1 Therapeutics (GTHX) and Logicbio The post Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Logicbio Therapeutics (LOGC) appeared first on Smarter Analyst .

Smarter Analyst | June 7, 2021

Raymond James Keeps Their Buy Rating on G1 Therapeutics (GTHX)

In a report released today, Dane Leone from Raymond James maintained a Buy rating on G1 Therapeutics (GTHX). The companys shares closed last The post Raymond James Keeps Their Buy Rating on G1 Therapeutics (GTHX) appeared first on Smarter Analyst .

Smarter Analyst | June 4, 2021

G1 Therapeutics (GTHX) Receives a Buy from Needham

Needham analyst Chad Messer reiterated a Buy rating on G1 Therapeutics (GTHX) today and set a price target of $68.00. The post G1 Therapeutics (GTHX) Receives a Buy from Needham appeared first on Smarter Analyst .

Smarter Analyst | June 4, 2021

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 44,200 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employee’s becoming an employee of G1 in accordance with Na

Yahoo | June 4, 2021

G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer

- Combination of Rintodestrant and Palbociclib was Very Well Tolerated with No Reported Discontinuations due to Treatment-Emergent Adverse Events (TEAEs) - - 60% Clinical Benefit Rate Achieved in Full Analysis Set at Week 24 - RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from its Phase 1 study of its oral selective estrogen receptor degrader (SERD), rintodestrant, demonstrating t

Yahoo | June 4, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6366 seconds.